Sandimmun Optoral

PreclinicalSmall molecule

Sandimmun Optoral is one of 3 small molecule programs targeting Heart Transplant Rejection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart Transplant RejectionUnknown

Heart Transplant RejectionPreclinical

Unknown

Competition

Competitive Landscape

2 competitors in Heart Transplant Rejection

#DrugCompanyPhaseTrials

Nulojix

Optison

1 3

Sandimmun Optoral

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Completed· Novartis logo

Novartis·Phase 3·NCT00514514·802 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sandimmun Optoral. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandimmun Optoral compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandimmun Optoral. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

Sandimmun Optoral

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News